Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

Coronary Artery Disease Clinical Trial

— ELITE  

Official title:

A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00715884
• Other study ID #: P07-6330
• Status: Active, not recruiting
• Phase: N/A
• First received: July 11, 2008
• Last updated: December 17, 2013
• Start date: July 2008
• Est. completion date: September 2014

Study information

• Verified date: December 2013
• Source: Cordis Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.

Description:

A prospective, single-blind, randomized, multicenter, two arm study. The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 678
• Est. completion date: September 2014
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with de novo atherosclerotic CAD in 1 or 2 vessels;

• The subject must be >/= 18 years of age;

• Female of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment;

• Diagnosis of angina pectoris as defined by stable angina pectoris Canadian Cardiovascular Society Classification (Class I, II, III) OR non-ST segment elevation acute coronary syndrome (Braunwald Classification B&C) OR non-ST segment elevation myocardial infarction >/= 48 hours from the time of study index procedure OR asymptomatic subjects with a positive stress test;

• Treatment of </= two lesions in one or two major coronary arteries (1 target lesion in each of 2 vessels or 2 target lesions in 1 vessel);

• Target vessel diameter must be >/= 2.25mm and </= 4.0 in diameter (visual estimate);

• Target lesion stenosis is > 50% and < 100% (visual estimate);

• Target lesion length <30mm (for each target lesion(s)) with a total implanted stent length < 66mm. Additional stents can be used to treat dissections, etc,: however, these must be the same stent to which the subject has been randomized in the study.

• Subject or Legally Authorized Representative must provide written informed consent prior to the procedure using a form that is approved by the Institutional Review Board/Independent Ethics Committee.

Exclusion Criteria:

• ST Segment Elevation Myocardial Infarction (STEMI) within 30 days of the study index procedure;

• Unprotected left main coronary disease with >/= 50% stenosis;

• Total coronary occlusion or TIMI grade 0 or 1 in the target vessel;

• Angiographic evidence of thrombus within target lesion(s);

• Calcified target lesion(s) which cannot be, in the investigator's opinion, successfully pre-dilated;

• Bifurcation disease involving a side branch >/= 2 mm in diameter;

• Prior stent within 5 mm of target lesion(s);

• Ostial target lesion(s);

• Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial graft);

• Documented left ventricular ejection fraction </= 25%;

• Impaired renal function (creatinine > 250 µmol/L or > 2.5 mg/dl) at the time of treatment;

• Pretreatment with devices other than conventional balloon angioplasty;

• Significant angulation in the target vessel that, in the Investigator's opinion, may preclude stent delivery and deployment;

• Subject previously treated with brachytherapy;

• Recipient of heart transplant;

• Subject with a life expectancy less than 12 months;

• Known allergies to the following: aspirin, clopidogrel bisulfate and ticlopidine, heparin, stainless steel, contrast agent (that cannot be managed medically), or sirolimus that cannot be managed medically;

• Any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study;

• Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints;

• In the Investigator's opinion, the lesion is not suitable for stenting;

• Known bleeding or hypercoagulable disorder;

• Known or suspected active infection at the time of the study procedures;

• Subject is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser;

• Subject has had major surgical or interventional procedures unrelated to this study within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atherosclerosis
• Coronary Artery Disease
• Coronary Atherosclerosis
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• CYPHER® ELITE™ Sirolimus-Eluting Stent System
Drug eluting stent
• CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
Drug eluting stent

Locations

Country	Name	City	State
United States	Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cordis Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experienced Target Lesion Failure (TLF)	The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.	12-months post-procedure	Yes
Secondary	Percentage of Lesion Success	Lesion success is defined as the attainment of < 50 percent residual stenosis (by Quantitative Coronary Angiography (QCA)) using any percutaneous method.	At procedure	Yes
Secondary	Percentage of Device Success - Protocol Definition	Device success is defined as achievement of a final residual diameter stenosis of <50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. Protocol definition: Only protocol-defined study stents were included.	At procedure	Yes
Secondary	Percentage of Device Success - All CYPHER® Stents Included	Device success is defined as achievement of a final residual diameter stenosis of <50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. All CYPHER® Stents were included if the final residual stenosis was <50%. Non-study CYPHER® Stents were also included.	At procedure	Yes
Secondary	Percentage of Participants Who Achieved Procedure Success	Procedure success is defined as achievement of a final diameter stenosis of < 50 percent (by QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion during the hospital stay.	At procedure during hospital stay	Yes
Secondary	Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)	TLR is defined as any "clinically-driven" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic electrocardiogram (ECG) changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.	12 months post-procedure	Yes
Secondary	Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)	TVR is defined as any "clinically driven" repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Target Vessel Failure (TVF)	Target Vessel failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)	MAJOR ADVERSE CARDIAC EVENTS (MACE) consists of death, myocardial infarction, emergent bypass surgery, and target lesion revascularization.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)	A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)	A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Bleeding Complications	Bleeding complications include any bleeding events defined by THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI), Global Strategies for Opening Occluded Coronary Arteries (GUSTO), and "Protocol" definitions.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Died	Death incidences include both Cardiac and non-cardiac death.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Any Myocardial Infarction (MI)	Myocardial Infarction includes both Q-wave and WHO Non-Q Wave Myocardial Infarction events.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Stroke	The stroke definition includes both hemorrhagic and non-hemorrhagic strokes.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)	Protocol defined Stent thrombosis include both Early and Late Thrombosis. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave MI, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring > 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site-reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)	Academic Research Consortium (ARC) defines STENT THROMBOSIS as consisting of the following: DEFINITE - Angiographic or pathologic confirmation; PROBABLE - Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent; POSSIBLE - Any unexplained death > 30 days.; ARC Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points.	12 months post procedure	Yes
Secondary	Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)	Those ARC stent thromboses occurred between 0 and 30 days post-procedure are early stent thrombosis.	0-30 days post-procedure	Yes
Secondary	Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)	Those ARC stent thromboses occurred between 31 to 360 days post-procedure are late stent thrombosis.	31-360 days post-procedure	Yes